Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...

Abbisko announces positive results from phase 3 MANEUVER study of pimicotinib to treat tenosynovial giant cell tumour: Shanghai Wednesday, November 13, 2024, 18:00 Hrs [IST] Abbis ...

Target patient enrollment of 92 evaluable patients achieved in the VIRAGE Phase 2b clinical trial of VCN-01 in patients with metastatic ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

Abbisko’s small molecule drug pimicotinib has smashed the primary goal of a phase 3 trial for the treatment of tenosynovial ...

Dr. Endell obtained a PhD from LMU Munich, where he specialized in viral gene therapy aimed at addressing pre-existing ... checkpoint to dampen down the activation of specific immune cell subsets in ...

The Cas nuclease market is on an upward trajectory, forecasted to grow from $2.75 billion in 2023 to $3.27 billion in 2024, at a CAGR of 18.9%. Key drivers include the rapid advancements in genome ...

KOMET phase III trial of Koselugo shows statistically significant and clinically meaningful ORR vs. placebo in adults with neurofibromatosis type 1: Cambridge, UK Wednesday, Novem ...

Dr. Endell obtained a PhD from LMU Munich, where he specialized in viral gene therapy aimed at addressing pre-existing ... checkpoint to dampen down the activation of specific immune cell subsets in ...

One investigation discussed during the call involves sales reps in China allegedly changing genetic testing results to secure reimbursement for Tagrisso.